AstraZeneca Pharma India Ltd. — Board/Management Information 2021

Dec 30, 2021

==> picture [495 x 86] intentionally omitted <==

December 30, 2021

The Manager – Listing BSE Limited , 1[st] Floor, New Trading Ring Rotunda Buiding, P J Towers, Dalal Street, Fort, Mumbai 400001

The Manager – Listing National Stock Exchange of India Ltd. Exchange plaza, 5[th] Floor, Plot No.C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai 400051

Dear Sir(s),

Sub: Appointment of Ms. Shilpa Shridhar Divekar as an Additional Director (Non-Executive & Independent)

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015), we wish to inform you that the Board of Directors of the Company based on the recommendations of Nomination and Remuneration Committee, approved the appointment of Ms. Shilpa Shridhar Divekar (DIN: 06619353) as an Additional Director (Non-executive & Independent) of the Company w.e.f December 29, 2021.

The requisite details of the appointment pursuant to Regulation 30 of the Listing Regulations read with SEBI Circular dated September 9, 2015, are given as Annexure A.

We request you to please take the same on record.

Thanking you,

For AstraZeneca Pharma India Limited

BHUVANA Digitally signed by BHUVANAGIRI GIRI RUDRA RUDRA PRATAP PRATAP Date: 2021.12.30 20:27:43 +05'30' Pratap Rudra Company Secretary & Legal Counsel

Encl: As above

==> picture [452 x 65] intentionally omitted <==

==> picture [495 x 86] intentionally omitted <==

Annexure A

Sl.No		Particulars	Details
1		Reason for change Viz. appointment, ~~resignation,~~ ~~removal, death or otherwise~~	Appointment of Ms. Shilpa Shridhar Divekar as an Additional Director (Non-Executive & Independent).
2		Date of Appointment/ ~~Cessation/~~Term of appointment	Date: December 29, 2021 Term: Five years commencing from December 29, 2021 subject to approval of shareholders.
3		Brief Profile	Ms. Shilpa Shridhar Divekar has over two decades of rich experience across consulting and food & agriculture sectors. As part of her leadership journey, she led Regional Business Strategy for Asia Pacific and co-led Global Smallholder Strategy at Bayer CropScience. She served as the Chief Executive Officer of Monsanto India from 2014 to 2018 and was also responsible as Managing Director of the publicly listed entity in India. Prior to her 12 years stint at Bayer and Monsanto, she was the Head of Strategy & Business Development for Bunge India, a US headquartered multinational involved in oilseeds, commodity trading & foods. She started her career journey in 1996 at Arthur Andersen and KPMG, and gained significant experience serving clients in diverse industry sectors. Since April 2020, she has chosen to be a mentor to businesses seeking to turnaround, grow or start-up. In 2017, she was recognised among the Top 50 Most Powerful Women Leaders by Fortune India. She holds a Master in Business Administration from S. P. Jain Institute of Management & Research and she is a Chartered Accountant and Cost & Works Accountant.
4		Disclosure of Relationships between Directors	Ms. Shilpa Shridhar Divekar is not related to any of the Directors of the Company.
5		Affirmation pursuant to circular no. LIST/COMP/14/2018‐19 and circular no. NSE/CML/2018/02 dated June 20, 2018 issued by BSE and NSE	Ms. Shilpa Shridhar Divekar is not debarred from holding the office of Director by virtue of any SEBI Order or any such Authority.

==> picture [452 x 65] intentionally omitted <==